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Object. Cerebral vasospasm that is caused by aneurysmal subarachnoid hemorrhage and that is refractory to maximal 
medical management can be treated with selective intraarterial papaverine infusions. The effects of single papaverine treat­
ments on cerebral circulation time are well known. The purpose of this study was to assess the efficacy of multiple, repeat­
ed papaverine infusions on the cerebral circulation time in patients with recurrent vasospasm.
Methods. A retrospective study was conducted in 17 patients who received multiple intraarterial papaverine infusions 
in 91 carotid artery (CA) territories for the treatment of cerebral vasospasm. Cerebral circulation times were measured from 
the first angiographic image, in which peak contrast was seen above the supraclinoid internal CA, to the peak filling of 
cortical veins. Glasgow Outcome Scale (GOS) scores assessed 12 months after discharge were reviewed. Cerebral circula­
tion times in 16 CA territories were measured in a control group of 11 patients.
Seventeen patients received a total of 91 papaverine treatments. Prolonged cerebral circulation times improved after 90 
(99%) of 91 papaverine treatments. The prepapaverine mean cerebral circulation time was 6.54 seconds (range 3.35-27 
seconds) and the immediate postpapaverine mean cerebral circulation time was 4.19 seconds (range 2.1-12.6 seconds), an 
overall mean decrease of 2.35 seconds (36%, p <  0.001). Recurrent vasospasm reflected by prolonged cerebral circulation 
times continued to improve with subsequent papaverine infusions. Repeated infusions were just as successful quantitative­
ly as the primary treatment (mean change 2.06 seconds). The mean cerebral circulation time in the control group was 5.21 
seconds (range 4-6.8 seconds). In five patients a dramatic reversal of low-attenuation changes was detected on compu­
terized tomography scans. The mean GOS score at 12 months after discharge was 3.4.
Conclusions. The preliminary results indicate that multiple intraarterial papaverine treatments consistently improve ce­
rebral circulation times, even with repeated infusions in cases of recurrent vasospasm.
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C ereb ra l vasospasm caused by aneurysmal SAH continues to be a disabling disease associated with high risks of morbidity and death. Furthermore, it is 
the most common cause of delayed neurological deficits, 
affecting up to 30% of patients who survive the initial hem- 
orrhage.17,23 Current therapy for prevention and treatment 
of symptomatic vasospasm includes triple-H therapy,1 Ca 
channel antagonists,2 and early surgery with clot removal.15 
if, however, vasospasm is refractory to medical manage­
ment, endovascular therapy, consisting of selective intraar- 
terial papaverine infusions, transluminal balloon angioplas­
ty, or a combination of these treatments, has been used.8,25,35 
The primary goal of endovascular treatment for symptom­
atic vasospasm is to increase CBF to prevent infarction. 
intraarterial papaverine infusions have been used to re-
Abbreviations used in this paper: CA = carotid artery; CBF = 
cerebral blood flow; CT = computerized tomography; DS = digital 
subtraction; GOS = Glasgow Outcome Scale; ICA = internal CA; 
ICP = intracranial pressure; MCA = middle cerebral artery; rCBF = 
regional CBF; SAH = subarachnoid hemorrhage.
subarachnoid hemorrhage • papaverine •
verse angiographically and clinically evident vasospasm,
with some success.9,21,22,24,32,40 Papaverine improves CBF
by dilating the proximal, intermediate, and distal cerebral 
arteries; effectively increases angiographically demonstrat­
ed vessel diameter;32 improves mean circulation time;31 and 
improves cerebral oxygenation.9 Nevertheless, one of the 
major disadvantages of papaverine infusion is its transient 
nature, resulting in recurrent and/or persistent angiograph- 
ically and clinically evident vasospasm that may require 
multiple repeated infusions despite a successful response to 
the initial treatment.4,32,36 The purpose of this study was to 
assess the efficacy of multiple intraarterial papaverine infu­
sions in patients with recurrent cerebral vasospasm by mea­
suring cerebral circulation time.13,31
Clinical M aterial and M ethods 
Patient Population
Aneurysmal SAH databases covering the period from 
July 1996 to December 2002 were reviewed at two institu-
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tions: Westchester Medical Center, Valhalla, New York; and 
university of u tah Health Sciences Center, Salt Lake City, 
Utah. A total of 512 patients were admitted with a diagno­
sis of aneurysmal SAH. Of these, 115 patients (57 from 
Westchester Medical Center and 58 from University of 
Utah Health Sciences Center) received intraarterial papav­
erine infusions for symptomatic vasospasm. Seventeen of 
115 patients (four treated at Westchester and 13 at the Uni­
versity of Utah) received multiple intraarterial papaverine 
infusions. Patients who received a single papaverine treat­
ment were excluded from this study. The charts, opera­
tive records, radiographic studies, and angiograms were re­
viewed for the 17 patients in this series, whose ages ranged 
from 20 to 83 years (mean 52 years). The male/female ratio 
was 6:11.
Diagnosis and Evaluation o f  Vasospasm
All 17 patients exhibited symptomatic vasospasm that 
was refractory to maximal medical management with tri- 
ple-H therapy and Ca channel blockers. Daily transcranial 
Doppler ultrasonography studies were performed as a rou­
tine noninvasive surveillance method for vasospasm. Clin­
ical vasospasm was diagnosed after the occurrence of a new 
neurological deficit or a decreased level of consciousness 
not attributed to hydrocephalus. All patients who exhibited 
clinical vasospasm underwent cerebral angiography to con­
firm vasospasm with radiographic evidence.
Intraarterial Infusion o f  Papaverine
In all 17 patients the ruptured aneurysm was occluded 
from the cerebral circulation by using microsurgical clip li­
gation (14 patients), vessel wrapping (one patient), or coil 
embolization (two patients) prior to papaverine treatments. 
Intraarterial papaverine hydrochloride was infused into the 
supraclinoid segment of the CA. The mean total dose in 
each CA territory was 140 mg, with a range of 60 to 165 
mg. The infusion was mixed with normal saline at a con­
centration of 0.3% and was typically administered at a rate 
of 3 ml/min. The rate of infusion was adjusted according to 
changes in ICP, which was monitored continuously through 
an external ventricular drain in all patients receiving papav­
erine.
Angiographic Evaluation o f  Cerebral Circulation Time
Using DS angiography, the cerebral circulation time was 
calculated before and after intraarterial papaverine infu­
sions. The observed cerebral circulation time was measured 
based on the definition by Milburn, et al.,31 which calculates 
the interval between the first image in which contrast mate­
rial is visible above the supraclinoid ICA and the peak fill­
ing of the cortical parietal veins. The original tapes for each 
angiographic run were retrieved to view all the images used 
to calculate cerebral circulation time. The images were ac­
quired at 3.8 frames/second for the first 5 seconds and one 
frame/second thereafter; this filming sequence requires in­
terpolation of frame numbers to measure cerebral circula­
tion time. As a control population, we studied 11 consec­
utive patients who underwent cerebral angiography for CA 
atherosclerotic disease who had no evidence of ipsilateral 
intracranial or extracranial stenosis, tumor, unruptured an­
eurysm, or vascular malformation. The comparison of ce­
rebral circulation times before and after papaverine treat-
Fig. 1. Bar graph showing improvement in mean cerebral circu­
lation time after intraarterial papaverine infusion in 91 treatments 
(p 0.001). CCT1 = prepapaverine cerebral circulation time; 
CCT2  = postpapaverine cerebral circulation time.
ment was performed using paired Student t-tests. The level 
of statistical significance was selected at a probability value 
of less than 0.05.
Evaluation o f  Treatment
New neurological deficits caused by vasospasm and 
changes in the results of neurological examinations per­
formed after papaverine treatment were documented. The 
initial admission Glasgow Coma Scale and GOS19 scores at
12 months after discharge were documented. When avail­
able, unenhanced CT scans obtained before intraarterial pa­
paverine infusion were compared with postpapaverine neu­
roimages; these images were evaluated for the reversal of 
low-attenuation changes.
Results
In this series, intraarterial papaverine infusions for the 
treatment of vasospasm were instituted in 115 (22.5%) of 
512 of the patients with aneurysmal SAH. Of the patients 
who received intraarterial papaverine, 17 (14.8%) of 115 
underwent multiple infusions; a total of 91 papaverine infu­
sions were performed in these 17 patients (Table 1). In 16 
patients papaverine infusions were administered in bilateral 
CA territories, whereas in one patient repeated papaverine 
infusions were given in a unilateral CA territory. The num­
ber of papaverine infusions per patient ranged from two to
11 (mean 5.35), and the number of repeated papaverine in­
fusions administered in a CA territory (left or right ICA) 
ranged from two to seven.
Prolonged cerebral circulation times improved after 90 
(99%) of 91 papaverine treatments. The prepapaverine 
mean cerebral circulation time was 6.54 seconds (range 
3.35-27 seconds) and the immediate postpapaverine mean 
cerebral circulation time was 4.19 seconds (range 2.1-12.6 
seconds), an overall decrease of 36% (p <  0.001; Fig. 1). 
The mean cerebral circulation time in the control group was 
5.21 seconds (range 4-6.8 seconds).
Recurrent vasospasm was reflected by prolonged cere­
bral circulation times after previous successful papaverine 
infusions. In 15 cases, repeated papaverine infusions were 
given on consecutive days within a 24-hour period. In se­
vere cases of diffuse cerebral vasospasm, papaverine was 
infused in bilateral CA territories. Twenty-seven CA territo­
ries were treated with a second infusion, 17 received a third 
treatment, 11 received a fourth treatment, four had a fifth 
treatment, two had a sixth treatment, and one had a seventh
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1 60, M II 2 14 4 lt MCA clip ligation 2 lt ICA 5.86 3.20 5
lt ICA 4.27 2.93 6
2 50, M III 3 15 4 lt PCoA clip ligation 2 lt ICA 6.80 5.73 5
lt ICA 5.87 5.60 6
3 20, M IV 3 5T 5 lt ICA clip ligation 5 lt ICA 7.60 4.00 4 improved low
bifurca­ rt ICA 7.34 4.00 5 attenuation on
tion lt ICA 3.73 3.46 5 CT scans,
lt ICA 5.34 3.46 7 improved
lt ICA 6.13 4.00 11 monoparesis
4 36, F IV 3 10T 3 lt PCoA wrapping 3 rt ICA 18.70 9.40 4 improved low
lt ICA 27.00 12.60 4 attenuation on
lt ICA 12.80 5.60 7 CT scans
5 34, F IV 3 10T 4 ACoA clip ligation 6 rt ICA 5.10 2.70 7 improved low
lt ICA 7.10 2.75 7 attenuation on
rt ICA 6.15 2.65 8 CT scans,
lt ICA 8.05 4.60 8 increased ICP
rt ICA 4.20 2.75 9
lt ICA 4.25 2.50 9
6 75, F IV 3 9T 3 ACoA coil 10 rt ICA 6.40 4.25 6
embol- lt ICA 7.20 5.80 6
ization rt ICA 6.45 3.30 7
lt ICA 7.40 5.55 7
rt ICA 6.25 3.35 8
lt ICA 5.50 2.43 8
rt ICA 4.75 2.65 9
lt ICA 5.45 2.60 9
rt ICA 5.70 5.45 10
rt ICA 5.25 3.85 11
7 50, F III 2 15 5 lt MCA clip ligation 2 lt ICA 6.25 5.10 4 improved aphasia,
lt ICA 6.30 5.00 5 improved low
attenuation on
CT scans
8 82, M IV 3 8T 3 ACoA coil 6 rt ICA 7.75 5.80 11
embol- lt ICA 7.75 5.50 11
ization rt ICA 4.20 4.10 12
lt ICA 5.80 3.30 12
rt ICA 5.05 3.15 13
lt ICA 4.05 2.35 13
9 47, M II 3 15 4 lt MCA clip ligation 6 rt ICA 5.00 3.10 7 improved aphasia,
lt ICA 5.85 2.70 7 improved low
lt ICA 5.05 3.00 9 attenuation on
rt ICA 3.85 3.20 10 CT scans
lt ICA 4.95 3.20 10
lt ICA 4.75 2.70 11
10 53, F IV 2 12 1 rt MCA clip ligation 7 rt ICA 4.85 3.75 7 death: pulmonary
lt ICA 4.85 2.85 7 embolus
lt ICA 5.05 4.00 8
rt ICA 4.25 2.80 9
lt ICA 5.15 3.40 9
rt ICA 5.00 2.70 10
lt ICA 5.10 3.25 10
11 38, F III 3 13 4 BA clip ligation 5 rt ICA 5.00 3.90 7 increased ICP
lt ICA 6.10 2.10 7
rt ICA 5.05 2.40 8
lt ICA 4.05 2.60 8
lt ICA 4.05 2.95 9
12 83, M IV 3 14 1 ACoA clip ligation 6 rt ICA 6.50 3.90 6 increased ICP,
rt ICA 8.55 3.30 11 death: support
lt ICA 6.75 2.75 11 withdrawn, lt
rt ICA 7.80 4.10 12 MCA stroke
lt ICA 6.00 3.50 12
rt ICA 7.75 4.40 13
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TABLE 1 (continued)
Characteristics o f  17 patients treated with multiple papaverine infusions fo r  recurrent vasospasm*
Grade or Score
12- Aneurysm Characteristics 
Case Age (yrs), Adm Mo











13 47, F IV 3 7T 5 rt PCoA clip ligation 9 rt ICA 4.85 4.70 6
lt ICA 9.50 5.80 6
rt ICA 6.10 4.10 7
lt ICA 6.85 5.60 7
rt ICA 6.80 4.50 8
lt ICA 8.55 5.55 8
rt ICA 7.60 5.00 9
lt ICA 6.85 5.30 9
rt ICA 6.05 3.90 10
14 52, F III 3 13 4 rt OphA clip ligation 11 rt ICA 9.70 7.05 4
rt ICA 11.30 8.15 5
lt ICA 6.75 5.00 5
rt ICA 7.55 5.35 6
lt ICA 4.05 3.10 6
rt ICA 10.65 7.50 7
lt ICA 5.05 3.05 7
rt ICA 9.55 7.35 8
lt ICA 5.05 3.05 8
rt ICA 8.35 5.05 9
rt ICA 7.30 6.20 11
15 47, F II 3 15 3 ACoA clip ligation 4 rt ICA 6.35 4.05 10
lt ICA 5.75 4.55 10
rt ICA 5.40 3.95 12
lt ICA 5.05 3.70 12
16 60, F III 3 12 1 ACoA clip ligation 5 lt ICA 4.35 3.00 5 death: support
lt ICA 3.35 3.60 6 withdrawn,
lt ICA 4.00 2.70 7 bilat ACA in-
lt ICA 6.30 4.00 10 farcts
lt ICA 5.70 4.30 11
17 52, F III 3 14 4 lt PCoA clip ligation 2 lt ICA 8.30 5.70 8 transient aphasia
lt ICA 7.05 4.60 8 from
papaverine
mean 3.40 6.54 4.19
* ACA = anterior cerebral artery; ACoA = anterior communicating artery; adm = admission; BA = basilar artery; GCS = Glasgow Coma Scale; H & H =
Hunt and Hess; OphA = ophthalmic artery; PCoA = posterior communicating artery; Tx = treatment.
treatment. Repeated infusions were just as successful quan­
titatively as the first treatment (Table 2, Figs. 2 and 3). The 
mean improvement in cerebral circulation time during the 
first papaverine treatment was 2.95 seconds. The mean im­
provement in cerebral circulation time after subsequent pa­
paverine treatments was 2.01 seconds for the second treat­
ment, 2.12 seconds for the third treatment, 2.36 seconds 
for the fourth treatment, 1.5 seconds for the fifth treatment, 
2.35 seconds for the sixth treatment, and 1.1 seconds for the 
seventh treatment.
Eight patients experienced improvement in their de­
pressed level of consciousness after papaverine infusion. In 
one patient reversal of an upper-extremity monoparesis oc­
curred, and in three patients there was improvement in 
vasospasm-induced aphasia. In five patients in whom an 
initial exacerbation of low-attenuation lesions was observed 
on CT scans, there was ultimately a reversal of radiograph- 
ically identified changes after multiple infusions of intraar- 
terial papaverine (Fig. 4).
In three patients the papaverine treatments were discon­
tinued before delivery of the target dose was completed, 
when ICP increased during infusion. One patient experi­
enced a transient, papaverine-induced aphasia with slowing
detected on electroencephalography. No other complica­
tions from intraarterial papaverine infusions were noted.
The mean GOS score at 12 months after discharge was 
3.4. Ten patients (59%) had a GOS score of 4 or 5 and were 
living independently at home. Four patients (24%) had a 
GOS score of 3 and were severely disabled. There were 
three deaths in our series of patients with refractory vaso-
TABLE 2










Reduction in Mean 
CCT After Tx (secs)
1 29 7.63 4.68 2.95
2 27 6.00 3.99 2.01
3 17 5.50 3.38 2.12
4 11 6.40 4.04 2.36
5 4 6.75 5.25 1.50
6 2 6.80 4.45 2.35
7 1 7.30 6.20 1.10
mean 6.63 4.57 2.06
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Fig. 2. Boxplot showing change in cerebral circulation time me­
dian (line within box), 25th- and 75th-percentile (lower and upper 
boundaries of box), and 5th- and 95th-percentile (whiskers) values.
spasm: one patient died of a massive pulmonary embolus, 
and the other two underwent withdrawal of care after suf­
fering from debilitating cerebral infarcts (one in the left 
MCA distribution and one in the bilateral anterior cerebral 
artery distribution).
Discussion
Since the initial reports of Kaku, et al.,21 and Kassell, et 
al.,22 the use of intraarterial papaverine to treat symptomatic 
vasospasm induced by aneurysmal SAH has increased.4,9,10, 
24,27,32 Papaverine is an alkaloid of the opium group that has 
potent vasodilating effects through direct action on smooth 
muscle. Although the mechanism is not completely un­
derstood, papaverine is thought to inhibit cyclic adenosine 
monophosphate and cyclic guanosine monophosphate 
phosphodiesterases in smooth muscles to increase intracel­
lular levels of both substances.26 It also may work by block­
ing Ca ion channels in the cell membrane and inhibiting the 
release of Ca from the intracellular space.35
Papaverine improves CBF by dilating the proximal, in­
termediate, and distal cerebral arteries, effectively increas­
ing angiographically observed vessel diameter,32 improving 
mean circulation time,31 and improving cerebral oxygena- 
tion.9 Nevertheless, its efficacy in improving neurological 
outcome remains inconclusive.4,10,20-22,27 At various neuro­
surgical centers,24,39 intraarterial papaverine continues to be 
a mainstay of endovascular treatment of vasospasm refrac­
tory to medical management. Even though the successful 
use of papaverine has been reported anecdotally, its clinical 
benefit and its precise role in treating vasospasm have yet to 
be determined in controlled prospective studies. Our data 
demonstrate that repeated papaverine infusions are as effec­
tive as the initial one.
Measurement o f  Cerebral Circulation Time
Assessments of rCBF can be performed using positron 
emission tomography, Xe-CT, or single-photon emission 
CT scanning; however, these modalities are not widely 
available. Cerebral circulation time, which can be readily
( j
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Fig. 3. Graph displaying results in an illustrative example (Case 
14). The graph demonstrates repeated improvement of cerebral cir­
culation time after multiple papaverine infusions in the right iCA 
territory.
calculated based on results of conventional angiography 
studies, is proportional to mean transit time and can be used 
to evaluate cerebral hemodynamics.11,14 Cerebral circulation 
time measurements can be useful for evaluating cerebral 
vasospasm and rCBF.34,37,38 Using both DS angiography 
and single-photon emission CT scanning, Ohkuma, et al.,37 
demonstrated an inverse correlation between cerebral circu­
lation time and rCBF in patients with cerebral vasospasm. 
Thus, prolonged cerebral circulation time may correlate 
with decreased CBF.
The measurement of cerebral circulation time may also 
be useful for evaluating the effects of endovascular treat­
ments, such as intraarterial papaverine infusion and/or an­
gioplasty, in patients with cerebral vasospasm.18,31,34 In our 
study, we have demonstrated that patients with clinically 
evident vasospasm exhibited a prolonged cerebral circula­
tion time when compared with the control group. There was 
also a consistent decrease (36%) in cerebral circulation time 
after intraarterial papaverine infusion (Fig. 1); these results 
are consistent with previous reports.18,31,34 Milburn, et al.,31 
showed a decrease in cerebral circulation time after intraar- 
terial papaverine infusions in 58 of 59 CA territories in 27 
patients. Iseda, et al.,18 showed a decrease in cerebral circu­
lation time in seven patients who received endovascular 
therapy (intraarterial papaverine alone or intraarterial pa­
paverine and angioplasty), which correlated with improve­
ments in CBF.
The methodology for measuring cerebral circulation time 
from angiography was originally described by Greitz.13,14 
Because not all images were filmed in our cases, we viewed 
the original tapes for each angiographic run. By viewing all 
the images, we could better define the start point and end 
point images to calculate a more accurate cerebral circula­
tion time. One disadvantage of DS angiography is that the 
images are not acquired in real time. Therefore, the inter­
polation of frame numbers to calculate cerebral circulation 
time may introduce some degree of error (3.8 frames/ 
second allows for <  0.3 second of error for each measure­
ment).
Severe vasospasm in the posterior circulation that war­
ranted endovascular therapy was observed in three patients 
in our series. Because cerebral circulation time measured in 
the vertebrobasilar circulation is different from that mea­
sured in the CA circulation,12 the data from these treatments 
were not included in the present study.
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Fig. 4. Case 9. Axial CT scans obtained in a patient with SAH, demonstrating reversal of low-attenuation changes after 
multiple papaverine infusions. Left: Prepapaverine CT scan obtained on post-SAH Day 7. Right: Postpapaverine CT 
scan obtained on post-SAH Day 151.
Multiple Papaverine Infusions
The results from our study indicate that repeated intra- 
arterial papaverine infusions consistently improve cerebral 
circulation time. Interestingly, each subsequent papaverine 
infusion achieved a similar magnitude of change, which 
demonstrates its efficacy on previously treated vessels (Ta­
ble 2, Figs. 2 and 3). Overall, there was a consistent re­
sponse to papaverine on repeated infusions (mean change 
2.06 seconds).
This patient series represents those who have severe, 
diffuse, refractory cerebral vasospasm manifested by pro­
longed circulation times. It has been our practice to inter­
vene aggressively with endovascular treatments at the ear­
liest onset of clinical vasospasm that has become refractory 
to maximal medical management. Despite favorable angio- 
graphically confirmed responses after papaverine infusion, 
recurrent vasospasm occurs frequently within 24 to 48 
hours.22,27 Its origin is not well understood but is probably 
due to the relatively short halflife of papaverine. The actu­
al effective halflife of smooth muscle relaxation after in- 
traarterial papaverine infusion has not been determined in 
human cerebral arteries but was reported to be less than 1 
hour in canine vasospasm models.43 If the halflife is truly 
shorter, clinical improvement is likely attributable to the 
additive effect of triple-H therapy after cerebral vasodila­
tion by papaverine treatment. There is some evidence that 
plasma levels of papaverine rise with continuous admin­
istration of the drug every 6 hours, which indicates a true 
halflife closer to 24 hours.6 This rise in basal plasma papav­
erine levels may be an additional mechanism by which mul­
tiple papaverine treatments received on consecutive days 
were effective in some patients in this series.
Repeated papaverine infusions may be a method for 
treating recurrent vasospasm, especially when it is more
diffuse and seen in more distal arteries in which angioplas­
ty is not possible. Numaguchi, et al.,36 reported that up to 
three infusions on consecutive days may be warranted if the 
patient’s general condition allows. Studies of CBF before or 
after infusion may aid in identifying regions of ischemia 
that require treatment, and in assessing improvement post­
treatment.44 One of the major disadvantages of papaverine 
therapy, as seen in our series, is the transient nature of its 
effects, resulting in recurrent and/or persistent angiograph- 
ically and clinically evident vasospasm that may require 
multiple infusions.43236
Effects o f  Papaverine on the Microcirculation
One major factor affecting cerebral ischemia during ce­
rebral vasospasm is the luminal narrowing of the large ex- 
traparenchymal arteries, which is often detected as angio- 
graphically confirmed vasospasm. In addition, vasospasm 
in the microcirculation, detected as prolonged peripheral 
cerebral circulation time (circulation time defined as the 
difference between the cortical segment of the rolandic ar­
tery and the rolandic vein), is also thought to be a factor 
contributing to cerebral ischemia. In some studies the in­
vestigators have suggested that vasospasm of the microcir­
culation plays a significant role in prolonging cerebral cir­
culation time and decreasing rCBF.34,37,38 Ohkuma, et al.,37 
measured both the proximal cerebral circulation time (cir­
culation time through the extraparenchymal large arteries) 
and the peripheral time (circulation time through the in- 
traparenchymal small vessels), and demonstrated that pro­
longed peripheral cerebral circulation time was associated 
with decreased rCBF in cases of severe angiographically 
confirmed vasospasm as well as in cases of absent or mild 
angiographically evident vasospasm. Compared with the 
overall circulation time, peripheral cerebral circulation time
J. Neurosurg. /  Volume 100 /  March, 2004 419
J. K. Liu, et al.
showed a stronger inverse correlation with rCBF. Pro­
longed peripheral cerebral circulation time may be related 
to impaired autoregulatory vasodilation or decreased lumi­
nal diameter in the microcirculation.
Complications o f  Intraarterial Papaverine Administration
The use of papaverine, however, is not without risk. Re­
ported complications include rapid increases in ICP,30 tran­
sient neurological deficits including mydriasis16 and brain­
stem depression,3,28 monocular blindness,4 seizures,4,27 
thrombocytopenia,33 precipitation of crystal emboli during 
infusion,29 and paradoxical exacerbation of vasospasm lead­
ing to cerebral infarction.5 Care should be taken when con­
centrations higher than 0.3% are used because the papaver­
ine may form a precipitate when mixed with blood. All 
of our patients underwent ICP monitoring7,30 during the pa­
paverine infusions. In this series, three patients exhibited 
increases in ICP during the papaverine infusion, which ne­
cessitated discontinuation of the treatment. After cessation 
of the infusions, the ICP returned to normal values. One pa­
tient experienced transient aphasia during the papaverine 
infusion, which resolved after treatment was stopped.
Reversal o f  Low-Attenuation Lesions Identified on 
CT Scans
In this study, there were five patients in whom an initial 
exacerbation of low-attenuation lesions was observed on 
CT scans, with ultimate reversal of radiographically ob­
served changes after multiple infusions of intraarterial pa­
paverine (Fig. 4). We have previously reported this interest­
ing phenomenon.24 Although these areas of low attenuation 
appear to represent areas of impending infarction, they most 
likely denote areas of edematous ischemic brain. Ischemic 
cytotoxic edema seen on CT scans is caused by the influx 
of water content due to the lowered electrochemical po­
tential of the neuronal plasma membrane.41 This potential 
is a result of ischemia-induced depletion of adenosine tri­
phosphate that leads to the inhibition of Na+/K+ adenosine 
triphosphatase activity, which leads, in turn, to increased in­
tracellular Na+ and decreased intracellular K+. If CBF is re­
stored in edematous ischemic brain before the tissue under­
goes irreversible cell death, the low-attenuation areas seen 
on CT scans can be reversed.
With repeated papaverine infusions, regions of low atten­
uation may become exacerbated before they are reversed. 
This phenomenon may be caused by a combination of re­
current vasospasm and postreperfusion cerebral hyperemia. 
During the period of ischemia, metabolic vasodilator prod­
ucts such as H , K , or adenosine accumulate and con­
tribute to increased CBF during reperfusion.42 Intravascular 
fluid then extravasates into the extravascular space through 
leaky ischemic vessels and contributes to more edema. The 
presence of low-attenuation changes on CT scans in some 
cases may represent reversible ischemic changes and may 
not be a contraindication to intraarterial papaverine treat­
ments. Nevertheless, one should be mindful of potential 
risks of reperfusion injury and hemorrhagic transformation 
after treatment in these situations.
Conclusions
Intraarterial papaverine retains a useful role in the treat­
ment of severe diffuse cerebral vasospasm. Papaverine adds 
the potential benefit of treating both large and small distal 
intracranial vessel segments that are not amenable to an­
gioplasty. Intraarterial papaverine is effective in decreasing 
prolonged cerebral circulation time. In cases of recurrent 
vasospasm, repeated papaverine infusions are as effective 
as the initial one in decreasing cerebral circulation time. 
Further studies are needed to compare improvement of ce­
rebral circulation time with clinical outcome.
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